Raymond H. Cypess, DVM, Ph.D.
Dr. Cypess is Chairman, President and CEO of ATCC and ATCC Global. In this role, he brings a unique blend of business acumen and fiscal responsibility, along with a visionary approach to the management of a non-profit/for-profit corporate structure. Over the past 25 years, he has applied innovative, non-traditional strategies to the reinvention and transformation of ATCC - completely rebuilding the financial foundation of the organization. Dr. Cypess holds a DVM from the University of Illinois and a Ph.D. in Parasitology from the University of North Carolina.
Prior to joining ATCC, Dr. Cypess was Dean of the College of Graduate Health Sciences, Professor of Microbiology, Immunology and Comparative Medicine, and Vice Provost for Research and Research Training, at the University of Tennessee, Memphis. During his leadership at the University, he created two new academic service departments - Biomedical Engineering and Comparative Medicine - as well as several center-wide core infrastructure units. Dr. Cypess also led a successful strategy significantly increasing the research funding of the University and was awarded the University of Tennessee Memphis College of Medicine Outstanding Teacher Award for 1989–1993. Prior to that, Dr. Cypess was an Associate Professor of Epidemiology and Microbiology at the University of Pittsburgh School of Public Health and Professor and Chairman at the New York State College of Veterinary Medicine.
Dr. Cypess participated on the National Institute of Allergy and Infectious Diseases (NIAID) scientific review boards and various NIH study sections and served on several editorial boards. He is the author of more than 80 chapters, reviews, and journal articles, a fellow in the Infectious Disease Society, and a member of the American Epidemiology Society. At ATCC, he has served as Principal Investigator on numerous grants and contracts, including the Malaria Research and Reference Reagent Resource Center (MR4) and the Biodefense and Emerging Infections Resources repository (BEI Resources) from NIAID. He has served on boards for the New York Stock Exchange and NASDAQ corporations, and has also been Director and Treasurer of the Virginia Biotechnology Authority.
Raymond D. Stapleton, Ph.D.
President and Chief Operating Officer
Ray is President and Chief Operating Officer of ATCC, and an Officer and member of the Board of Directors of both ATCC and ATCC Global. In this role, he leads ATCC’s corporate, business and customer care operations where he oversees the standardization, manufacture, and distribution of new tools and reagents to researchers around the globe. Ray brings extensive management experience to ATCC, including translational sciences and the application of Lean Six-Sigma management for biopharmaceutical companies.
With more than 20 years’ experience, Ray has led technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies. During his career, he has helped to provide leadership to multiple large CAPEX projects as well as the tech transfer and commercial launch of multiple billion-dollar biologic, vaccine and small molecule products.
Prior to joining ATCC, Ray was Senior Vice President of technical operations at the clinical stage biotechnology company Iovance Biotherapeutics, Inc. where key responsibilities included clinical and commercial supply chain, logistics, and commercial manufacturing readiness in support of the highly unique and complex cell therapy/personalized medicine. He was also Senior Vice President of manufacturing and technical operations at the microbiome- and GI-focused clinical stage biotechnology company Synthetic Biologics, Inc.
Previously, during his 15 year tenure at Merck and Company, Inc., he rose from process microbiologist, where he was recognized with a Technical Achievement Award for his development work on natural products fermentations, to leading a complex science, technology and engineering organization at a manufacturing site responsible for supporting Merck’s $5 billion vaccine business. Ray also has substantial experience with global regulatory boards of health including FDA, MHRA, EMA, ANVISA, and PMDA.
Ray earned a bachelor’s degree in Biology from Mary Washington College in Fredericksburg, Virginia and received his Ph.D. in Microbial Ecology from the University of Tennessee, Knoxville. A member of the American Society for Microbiology, he has served as peer reviewer for a several scientific journals and has co-authored 17 peer-reviewed manuscripts, as well as two patents.
Scott A. Siegel, Ph.D.
Vice President, Corporate Development and Chief Business Officer
Scott is Vice President of Corporate Development and Chief Business Officer for ATCC. In this role, he leads ATCC’s overall growth and business development strategy, including efforts to identify and negotiate partnership and M&A opportunities that enhance and expand ATCC’s products and services portfolio.
Scott brings more than 25 years’ experience as a business and scientific leader in the biotech and pharma industries to this role. He joined ATCC from the non-profit Institute of Life Science Entrepreneurship, where he was co-founder and Vice President of Business Development for this New Jersey-based life sciences incubator and accelerator.
He founded Milestone Life Sciences, a business development and strategic advisory firm, and previously held senior business leadership roles at Ezose Sciences, Redpoint Bio, and Johnson & Johnson.
Scott earned his Ph.D. in Biochemistry from SUNY Downstate Medical Center, completed postdoctoral studies in Pharmacology at Yale University, and spent the early part of his career as an R&D leader in fast moving biotech and start-up companies, including Centocor and Phytera. He has more than 60 publications and patents and contributed to the development of three launched products, including as co-inventor of Remicade®, the blockbuster anti-TNF therapy used worldwide in the treatment of more than two million patients with autoimmune disorders. Scott previously served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and more recently as Lecturer in the MBA program at the Wharton School.
Mindy Goldsborough, Ph.D.
Chief Science and Technology Officer
Vice President and General Manager, ATCC Cell Systems
As the Chief Science and Technology Officer for ATCC, Mindy works across ATCC’s business units and functions to develop and implement the scientific and technology strategy in support of organizational goals. Additionally, she oversees the ATCC Cell Systems (ACS) business unit located within Maryland’s High Technology Corridor in Gaithersburg, MD. ACS is the innovative cell biology product and technology development arm of ATCC. Its current focus is in areas of functional cell biology supporting basic and translational research.
Prior to ATCC, Mindy was Director of R&D for BD Biosciences’ Advanced Bioprocessing group. Her previous work includes senior R&D roles at BD Biosciences’ Bioimaging business (formerly Atto Biosciences) and Life Technologies, where she led R&D efforts in DNA-based diagnostics, stem cell biology, forensics, and nucleic acid purification. Mindy has more than 25 years of product and technology development expertise in cell and molecular biology. Several products that she helped develop during her career are still market standards today.
Mindy earned her Ph.D. in Genetics from The George Washington University, and completed her dissertation research and post-doctoral work at The National Institutes of Health, National Cancer Institute.
Joseph Leonelli, Ph.D.
Vice President, ATCC Federal Solutions
Joe is Vice President of ATCC Federal Solutions (AFS). In this role, he is responsible for the overall strategy, management and growth of AFS programs, which include products and services for emerging infectious disease, biodefense, medical countermeasures, and global health security.
Prior to joining ATCC, Joe was Vice President for National Security Systems and Solutions for Engility, where he managed three business units providing systems and software engineering to DOD, DOJ, and Intelligence Community customers. He held leadership positions at various entities within Raytheon, Applied Signal Technology, Inc., General Dynamics, Battelle, and SRI International.
Joe is active with the National Defense Industrial Association (NDIA), Association of the U.S. Army (AUSA), Armed Forces Communications Electronics Association (AFCEA), and Advanced Technical Intelligence Association (ATIA). Joe earned his Ph.D. in Inorganic Chemistry from Indiana University.
Maryellen de Mars, Ph.D.
Vice President, Standards Resource Center
Maryellen is Vice President of ATCC’s Standards Resource Center (SRC), a business unit focused on standards and related services. The SRC includes the Central Acquisition Unit (CAU), the Standards Development Organization (SDO), Services and Metrology R&D.
Prior to joining ATCC, Maryellen was Chief Operating Officer and Vice President of Clinical Operations at USDS, Inc., an independent third party evaluating the performance of molecular diagnostic tests to support regulatory, reimbursement, and adoption efforts. She also served as Director of Clinical Biomarkers at Critical Path Institute (C-Path), leading collaborative efforts to evaluate and improve the use of clinical biomarkers and optimize the pathway for development of companion diagnostics. She served as Executive Director of Genomics Services and Director of Biorepository at Gene Logic, Inc., and led business development and marketing efforts at Life Technologies, Inc.
She earned her Ph.D. in Virology from the University of Texas, and completed postdoctoral training in transcriptional regulation at The Johns Hopkins University.
James J. Kramer, Ph.D.
Vice President, Operations
Jim is Vice President of Operations for ATCC. In this role, he oversees ATCC’s manufacturing, inventory/repository, supply chain, facilities, Quality Control/Quality Assurance, regulatory compliance, and distribution of ATCC’s biological products worldwide.
Prior to joining ATCC, Jim acquired significant subject matter and operational expertise in the fields of biomanufacturing, supply chain management, regulated biologics, commercial operations, quality systems, and GMP-cell banking. He was vice president at several global bioscience, medical device, and biopharmaceutical organizations including Immucor, Inc., Bioreliance, Talecris Biotherapeutics, and Serologicals Corporation, and held various positions at Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson Company.
Jim earned his Ph.D. in Biochemistry from the University of Medicine and Dentistry of New Jersey and completed postdoctoral training in Protein Biochemistry at The University of North Carolina at Chapel Hill.
John Sweeney, MBA, CPA
Vice President, Finance & Administration and Chief Financial Officer
John brings a wide range of experience to ATCC as both a finance and business leader, with expertise in financial analysis, budgeting, cash management and acquisitions, as well as a strong technical accounting background. John has over twenty years’ experience in the pharma / life sciences sector, including four years working overseas. Prior to joining ATCC, John was most recently Vice President of Finance for the US Division of Alvogen Group. John has also held leadership roles in organizations including Actavis and Purdue Pharma. John, a Certified Public Accountant, earned his bachelor’s degree in accounting at Western Connecticut State University and has an MBA from the Stern School of Business at New York University.
Daniel Kelly, BS
Chief Information Technology Officer
Dan is Chief Information Technology Officer (CITO). In his role he is responsible for developing and driving digital strategies that sustain ATCC’s current mission as well as extend the company’s reach into new technology-based business opportunities. Dan brings more than 30 years’ experience as a principle and innovative information technology executive in IT and operations management. He has encompassed multiple commercial and public market sectors, including manufacturing, healthcare, engineering and construction, life sciences and federal, state and local government.
A systems engineer by training, Dan has served in a number of executive leadership roles as a strategist, operator, technologist and change agent bringing digital-enabled business enhancements to varied operating models. As a division manager of Perot Systems, Dan served marquee customers with diverse management consulting, technology and business process solutions delivered from a global platform. After a 20-plus year career at Electronic Data Systems and Perot Systems, Dan served in a number of transformative CIO and COO roles at Apria Healthcare, MedRisk and Parsons Corporation.
Teri Sellars, SPHR, SHRM-SCP
Senior Director, Human Resources
Teri is Senior Director of Human Resources for ATCC. In this role, she is responsible for Human Capital strategy and for directing all of the people functions of the organization, including talent acquisition, development, engagement, and management; total rewards programs; HR regulatory compliance; talent data management; and leadership development.
Teri joined ATCC from Analytic Services, Inc. (ANSER), a non-profit corporation providing expertise to public sector clients in the arenas of national and homeland security. Prior to ANSER, Teri served in a number of HR leadership/business partner roles for small companies and for divisions of larger organizations, including Convergys Corporation, Freddie Mac, Wireless Facilities, Inc., and WCI Communities. Teri has years of experience in transforming the HR function, mergers, acquisitions and integrations, and standing up HR departments.
Teri received her bachelor’s degree in French Business Studies from the University of Illinois at Chicago and completed a year of study at the University of Paris - La Sorbonne in Paris, France. Teri holds her Senior Professional in Human Resources certification as well as her SHRM-Senior Certified Professional, and has served on the Board of the Dulles SHRM chapter.